HomeAI · summaries
Storia in 3 fonti
Japan Startup Tests Catheter Injection of iPS Heart Muscle Cells
Tokyo, June 13 (Jiji Press)--Japanese startup Heartseed Inc. has said it conducted a clinical trial to inject via catheter small masses of heart muscle cells produced from induced pluripotent stem, or iPS, cells into patients with severe heart failure. The Tokyo-based company,
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed
Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed
- ·
asahi.com
iPS細胞「心筋球」カテーテル移植、1例目を実施 慶大ベンチャー：朝日新聞
慶応大発ベンチャー「ハートシード」（東京都港区）は12日、iPS細胞からつくった心臓の筋肉の細胞を、重い心不全の患者にカテーテルを使って移植する治験の1例目を実施したと発表した。血管から入れるカテー…
- ·
adnkronos.com
Japan Startup Tests Catheter Injection of iPS Heart Muscle Cells
Tokyo, June 13 (Jiji Press)--Japanese startup Heartseed Inc. has said it conducted a clinical trial to inject via catheter small masses of heart muscle cells produced from induced…